Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS

OBJECTIVE: To evaluate (1) the frequency of aquaporin-4 antibody (AQP4-ab)-seropositive cases among patients treated with natalizumab (NAT) and previously diagnosed with MS (MS(NAT)) in a nationwide cohort, (2) the clinical course of NAT-treated AQP4-ab–seropositive neuromyelitis optica spectrum dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Gahlen, Anna, Trampe, Anne-Kathrin, Haupeltshofer, Steffen, Ringelstein, Marius, Aktas, Orhan, Berthele, Achim, Wildemann, Brigitte, Gold, Ralf, Jarius, Sven, Kleiter, Ingo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473957/
https://www.ncbi.nlm.nih.gov/pubmed/28642888
http://dx.doi.org/10.1212/NXI.0000000000000363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473957/
https://www.ncbi.nlm.nih.gov/pubmed/28642888
http://dx.doi.org/10.1212/NXI.0000000000000363

Ejemplares similares